the safety variables evaluated included adverse experiences , proarrhythmia , congestive heart failure , other cardiovascular effects , death , chest x-ray , ophthalmic examinations , neuroleptic phenothiazine effects and clinical laboratory tests .
C0018802
congestive heart failure
C0007226
cardiovascular